3 recruiting, 2 completed, 2 not yet recruiting. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 3, Completed 2, Not yet recruiting 2 |
| Phase 2 | 2 | Not yet recruiting 2 |
Follow Servier: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation S243249 600mg, S243249 400mg, S243249 450mg - Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Servier | 80 | 2026-10-20 | 2026-09-03 |
| A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies S241656, Posaconazole - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Servier | 64 | 2026-09-15 | 2026-07-22 |
| ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas PEPIDH1M vaccine + vorasidenib - Low Grade Glioma of Brain | Phase 1 | Recruiting | Katy Peters, MD, PhD | 48 | 2025-07-15 | 2026-08-24 |
| CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Rituximab - Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 7 | 2023-05-01 | 2026-03-06 |
| Venetoclax Basket Trial for High Risk Hematologic Malignancies Venetoclax, Azacitidine, Cytarabine - Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary | Phase 1 | Recruiting | Andrew E. Place, MD | 30 | 2023-03-29 | 2026-03-12 |
| Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects OSE-127, Placebo - Healthy Subjects | Phase 1 | Completed | OSE Immunotherapeutics | 63 | 2018-12-19 | 2019-12-12 |
| Pharmacokinetics of AGO178 in Participants With Liver Impairment AGO178 - Hepatic Impairment | Phase 1 | Completed | Novartis Pharmaceuticals | 32 | 2011-02-08 | 2021-05-11 |
Leukemia, Myeloid, Acute (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2) · Brain Neoplasms (1) · Colitis, Ulcerative (1) · GATA2 Deficiency (1) · Glioma (1) · Inflammatory Bowel Diseases (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1)
calaspargase pegol (2) · Azacitidine (1) · CVAD protocol (1) · Cortisone (1) · Cytarabine (1) · Dexamethasone (1) · Dexrazoxane (1) · Doxorubicin (1) · Hydrocortisone (1) · Leucovorin (1) · Methotrexate (1) · Rituximab (1) · Vincristine (1) · agomelatine (1) · asparaginase erwinia chrysanthemi recombinant (1)
United States (4) · Belgium (1)
Andrew E Place, MD, PhD (1) · Bijal Shah, MD (1) · Katherine Peters, MD, PhD (1)
2025 (2), 2018 (1)